Study Start-Up

Persistent delays and inefficiencies in COA licensing and translation stem from limited pre-license access and fragmented processes, making a strong case for providing outcome assessment measures earlier to reduce risk and accelerate trial start-up.

By leveraging the Fresh Start Effect at site initiation and shifting from passive training to demonstrated readiness, sponsors and CROs can turn trial launch into a powerful multiplier for early performance, compliance, and execution quality.

Emerging applications of AI/ML, automation, and digitization are helping sponsors cut clinical trial start-up times to as little as four weeks, reduce data errors, and enhance patient engagement—demonstrating how tech-enabled processes are reshaping trial efficiency and experience across the study lifecycle.

Overcoming the illusion of knowledge in clinical research can enhance decision-making, training, and project success—helping ensure trials run smoothly and effectively.

It takes a village to raise a trial, but most stakeholders are siloed on isolated islands.

The activation of each clinical trial involves hundreds of tasks, along with many dependencies and handoffs, some of which may be automated, but many require manual processes.

Amplifying the size and diversity of participant pools in clinical trials enhances statistical power and increases the generalizability of study findings.

Optimizing feasibility through increased data collection.

Similar to a world-class symphony, a curated site start-up model can accentuate its individual components and lead to swift starts for clinical trials.

With a major wave of post-COVID trial starts on the horizon, the industry’s need to accelerate clinical research through study start-up is intensifying.

Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.

Why? Because more often than not, you do not want to accrue only one participant to a clinical trial.

Despite the substantial difficulties associated with orphan drug trial recruitment, this segment of the drug development market is booming.